Clinical trials: sponsored by Zhejiang Cancer Hospital
Gastric Cancer, Healthy
Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer
This project aims to collect peripheral blood samples from newly diagnosed gastric cancer patients and healthy individuals. Various techniques such as cfDNA sequencing, proteomics, and fragmentomics will be employed to analyze…
- Trial name
- NCT05991947
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line…
- Conditions
- Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT06349044
- Testing
- Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）, Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Cancer Hospital
HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
This trial is a single center, single arm, open label clinical study aimed at evaluating the efficacy and safety of the combination therapy of Disitamab Vedotin and trastuzumab in the treatment of advanced HER-2 positive…
- Trial name
- NCT06572319
- Testing
- Disitamab Vedotin(RC48) Plus Tratuzumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
- Trial name
- Neoadjuvant (NCT06562920)
- Testing
- adebrelimab and chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Chemoradiotherapy
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
This trial is a prospective, randomized, controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of sintilimab as consolidation therapy in elderly patients with esophageal cancer who did not progress…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
- Trial name
- NCT06413342
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Zhejiang Cancer Hospital
Adjuvant Radiotherapy
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer.
- Trial name
- NCT06272214
- Testing
- Adjuvant radiotherapy, Observation
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Zhejiang Cancer Hospital
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy.
- Trial name
- NCT06086197
- Testing
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.
- Trial name
- NCT06437678
- Testing
- Liposomal Irinotecan Hydrochloride
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer
Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy
This study has established a multidisciplinary rehabilitation team to recruit patients who underwent radical D2 gastrectomy in multiple centers and divided them into a rehabilitation group and a control group.
- Trial name
- NCT06419140
- Testing
- Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03025958
- Testing
- Nimotuzumab, Radiation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Resectable Pancreas Carcinoma
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer
It is a single arm, open-label, multicenter, phase II cinical trial to evaluate the efficacy and safety of the Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection in first-line treatment…
- Trial name
- NCT06393166
- Testing
- Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma
- Trial name
- NCT06383533
- Testing
- Disitamab Vedotin Plus Cadonilimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Cancer
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
This is a prospective, open-label, multi-center, single-arm clinical trial
- Trial name
- ACHIEVE (NCT04808752)
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed…
- Trial name
- NCT06364826
- Testing
- Sintilimab, bevacizumab, gemcitabine, IMRT
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Extensive Stage Lung Small Cell Cancer
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment…
- Trial name
- NCT06350162
- Testing
- Serplulimab, Chest Radiation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Breast Cancer
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety of Eribulin combined with Sintilimab in the first-line treatment of unresectable locally advanced or metastatic HER2-negative breast…
- Trial name
- NCT06308939
- Testing
- Eribulin, Sintilimab
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer
Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
This study is a multicenter, open, and phase I dose increasing clinical study. Based on the UGT1A1 * 28 and * 6 genotypes of patients with locally advanced rectal cancer, determine the dose limiting toxicity (DLT) and maximum…
- Trial name
- NCT06300489
- Testing
- irinotecan liposomes+capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Propofol, Hypoxia
HFNC and Hypoxia/Desaturation During Radiofrequency Ablation Under Moderate Sedation: A Randomized Clinical Trial
Background: Propofol based sedated anesthesia was widely used in percutaneous radiofrequency ablation and hypoxia/desaturation is one of the most frequent adverse events during this procedure.
- Conditions
- Propofol, Hypoxia, Sedation Complication, Desaturation of Blood
- Trial name
- NCT05212064
- Testing
- high-flow oxygen nasal cannula therapy, nasal cannula oxygen therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
This is an open-label, single-arm, exploratory study planned to include 40 patients with HRD-positive HR +/HER2- advanced breast cancer treated with Adebrelimab in combination with fluzoparib.
- Conditions
- Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer, HRD Positive Advanced Breast Cancer
- Trial name
- NCT06254066
- Testing
- Adebrelimab plus Fluzoparib
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Epithelial Ovarian Cancer
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
The PamiAP will be a Phase II, single-arm, open label study to explore the efficacy and safety of Pamiparib treatment in patients with Epithelial Ovarian Cancer（EOC） who have had exposure to prior a PARP…
- Trial name
- NCT05489926
- Testing
- Pamiparib
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang Cancer Hospital